ephedrine/guaifenesin (Rx)

Brand and Other Names:Primatene Tablets, Bronkaid Dual Action Formula
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ephedrine/guaifenesin

tablet

  • 12.5mg/200mg (Primatene Tablets)
  • 25mg/400mg (Bronkaid Dual Action Formula)

Asthma

Indicated for temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest, shortness of breath ephedrine

12.5-25 mg/guaifenesin 200-400 mg PO q4hr PRN

Not to exceed ephedrine 150 mg/guaifenesin 2400 mg per 24 hr

Dosing Considerations

Use of ephedrine-containing products are not recommended for asthma treatment by current clinical practice guidelines

Global Initiative for Asthma (GINA) - http://ginasthma.org/wp-content/uploads/2016/01/GINA_Pocket_2015.pdf

National Asthma Education and Prevention Program (NAEPP) - http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines

Dosage Forms & Strengths

ephedrine/guaifenesin

tablet

  • 12.5mg/200mg (Primatene Tablets)
  • 25mg/400mg (Bronkaid Dual Action Formula)

Asthma

Indicated for temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest, shortness of breath ephedrine

<12 years: Safety and efficacy not established

≥12 years: 12.5-25 mg/guaifenesin 200-400 mg PO q4hr PRN

Not to exceed ephedrine 150 mg/guaifenesin 2400 mg per 24 hr

Dosing Considerations

Use of ephedrine-containing products are not recommended for asthma treatment by current clinical practice guidelines

Global Initiative for Asthma (GINA) - http://ginasthma.org/wp-content/uploads/2016/01/GINA_Pocket_2015.pdf

National Asthma Education and Prevention Program (NAEPP) - http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines

Next:

Interactions

Interaction Checker

and ephedrine/guaifenesin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Hypertension

            Tachycardia

            Emotional disturbance

            Headache

            Insomnia

            Nervousness

            Seizure

            Hypersensitivity reaction

            Tremor

            Cough

            Exacerbation of asthma

            Productive cough

            Previous
            Next:

            Warnings

            Contraindications

            If the diagnosis of asthma is not confirmed by physician

            Coadministration with MAOIs or within 2 wk after discontinuing an MAOI

            Documented hypersensitivity to any ingredients

            Cautions

            This product will not provide quick relief from asthma symptoms, as would an inhaled bronchodilator

            May cause hypertension or tachycardia; serious cardiovascular events (eg, MI, stroke, arrhythmias, including death) reported with use of dietary supplements containing ephedrine

            If you have been previously hospitalized for asthma, other prescription drugs for asthma should be used as directed by your physician

            Caution with heart disease, hypertension, diabetes, thyroid disease, seizures, narrow angle glaucoma, history of psychiatric or emotional condition, prostatic hypertrophy, productive cough, cough that lasts or is chronic (eg, owing to smoking, asthma, chronic bronchitis, emphysema)

            Because asthma may be life-threatening, see a physician if you

            • Are not better in 60 min
            • Symptoms worsen
            • Need to exceed recommended maximum dose
            • Take more than 100 mg ephedrine/1600 mg guaifenesin per 24 hr for ≥3 days/wk
            • Have ≥2 asthma attacks/wk
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Limited human data have not shown fetal harm with temporary oral use

            Lactation

            Ephedrine: Unknown if distributed in human breast milk

            Guaifenesin: Unknown if distributed in human breast milk

            Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Ephedrine: Alpha, beta-1, and beta-2 receptor agonist

            Guaifenesin: Expectorant; reduces viscosity of mucus by increasing effective respiratory tract hydration

            Pharmacokinetics

            Ephedrine

            • Peak plasma concentration: 20-80 ng/mL (PO)
            • Onset of action: 15-60 min (PO)
            • Duration: 3-5hr (PO)
            • Vd: 220-240 L
            • Metabolism: liver
            • Metabolites: p-hydroxyephedrine, p-hydroxynorephedrine, norephedrine, and their conjugates
            • Half-life: 4.85-6.47
            • Clearance: 25.5-34.1 L/hr
            • Excretion: urine

            Guaifenesin

            • Onset of action: 30 min
            • Duration: 4-6 hr
            • Metabolism: liver
            • Metabolite: b-(2-methoxyphenoxy) lactic acid
            • Half-life: 1 hr
            • Excretion: Urine
            Previous
            Next:

            Administration

            Oral Administration

            May take with or without food

            Storage

            Store at room temperature

            Avoid excessive heat and humidity

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.